Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells

Conclusion: Our findings provide a rationale for combined inhibition of RAS/RAF/MEK/ERK and STAT3 pathways in order to enhance anticancer effects against acute lymphoblastic leukemia cells.

Source: Cancer Genomics and Proteomics - August 27, 2020 Category: Cancer & Oncology Authors: JASEK-GAJDA, E., JURKOWSKA, H., JASIŃSKA, M., LITWIN, J. A., LIS, G. J. Tags: Experimental Studies Source Type: research